Orchestrating the immune Response

Engineering precision immunity

Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including cell therapy activators, immunomodulators, and vaccines to defeat an array of aggressive cancers.


Lymph nodes:
where the immune response is orchestrated

Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine, Ph.D., a Howard Hughes Medical Institute investigator and professor at the Koch Institute of Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphiphiles target and concentrate in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.  Elicio is developing this approach to deliver next generation therapies, with lead programs in KRAS-driven cancers and CAR-T cell activators for CD19, BCMA, and multiple solid cancers. 





Our programs

Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2020. This program consists of an Amphiphile vaccine that has the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and 40% of colorectal cancers.



Latest News

ENDPOINTS: Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million
Darrell Irvine co-founded Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million. The company says that the financing will advance Elicio’s pipeline, including its amphiphile mKRAS vaccine, ELI-002 — which targets seven KRAS mutations that drive 99% of all KRAS-driven cancers. Investors for the round included Clal Biotechnology […] » Read more
BioWorld: Where the action is: Elicio $33M series B powers bid aimed at lymph in cancer
CEO Robert Connelly acknowledged "a general malaise about cancer vaccines," but described the strategy of his firm to BioWorld as "very different. None of these other approaches [has] delivered the goods to the lymph nodes, where the immune response is orchestrated." Cambridge, Mass.-based Elicio pulled down $33 million in a series B financing to advance lymph node-targeted immunotherapies that include ELI-002, an Amphiphile KRAS vaccine that takes aim at all seven of the KRAS mutations driving 99% of mutant KRAS cancers – a group estimated to take up 25% of all human solid tumors. » Read more